Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. Being a potentially life threatening disease and expensive to treat, the overall healthcare system views the treatment for this condition as a strategically critical area to address. This report analyzes the market for atrial fibrillation market from the point of view of various pharmacological and non-pharmacological treatment products used for the treatment of AF.
The pharmacological AF treatment market has been further classified into the specific drugs commonly used for treating AF, namely anti-arrythmics and anti-coagulants. The non-pharmacological atrial fibrillation devices market has been further sub-divided into therapeutic procedures such as catheter ablation procedures, maze surgery and electric cardioversion. The major methods of catheter ablation procedures studied in this report include radiofrequency, high intensity focused ultrasound (HIFU), cryoablation, microwave ablation and laser catheter ablation. Each of these segments and their sub-classification is analyzed on the basis of their market size and their forecast for the period 2011 to 2019, in terms of USD million. The compounded annual growth rate (CAGR) for all the above segments has been provided for the forecast period from 2013 o 2019, considering 2012 as the base year.
In terms of geography, the market for atrial fibrillation treatment has been categorized into four geographical markets namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for all the major segments, along with their growth rate, by regions has been provided in the report. The market overview section of the report includes the qualitative analysis of the atrial fibrillation treatment market in terms of environmental factors such as drivers, restraints and opportunities, market attractiveness analysis and Porter’s five forces analysis.
The report is concluded with the competitive landscape section which comprises the strategic recommendations for the current and future market players and company profiles of the existing market players in terms of their market share (value %) for the year 2012. Some of the major market players profiled in the report include St. Jude Medical, Boehringer Ingelheim, Boston Scientific Corporation, AtriCure, Inc., Johnson & Johnson and Bayer (Xeralto), Sanofi, CardioFocus, Endoscopic Technologies, Bristol Myers-Pfizer, Biosense Wesbter and others.
The global atrial fibrillation market is categorized into the following segments: